Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 9 of 25

COMPLETED NA

Cryovagotomy Diabetes Trial

NCT04276051

COMPLETED

Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women

NCT04531943

COMPLETED NA

Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad

NCT04426838

COMPLETED Phase 4

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

NCT04352101

COMPLETED NA

Healthy Homes/Healthy Families (HH/HF) Intervention in 2-1-1 Callers

NCT04373434

COMPLETED NA

Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation

NCT04409301

COMPLETED Phase 4

Are Opioids Needed After ACL Reconstruction

NCT04285853

COMPLETED Phase 2

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

NCT04524702

COMPLETED NA

Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia

NCT03818516

COMPLETED NA

iTransition Development

NCT04383223

COMPLETED NA

GO2 PEEP Study: Bidirectional Oxygenation Valve in Postoperative Atelectasis

NCT04253834

TERMINATED Phase 2

Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma

NCT04495894

COMPLETED Phase 4

Dapagliflozin at Discharge on Hospital Heart Failure Readmission

NCT04249778

COMPLETED Phase 4

Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity

NCT04441996

COMPLETED Early Phase 1

Convalescent Plasma in Pediatric COVID-19

NCT04458363

TERMINATED Phase 2

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

NCT04352205

COMPLETED Phase 1

WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors

NCT04334863

TERMINATED Phase 1

Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19

NCT04366791

COMPLETED NA

Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19

NCT04331366

COMPLETED Phase 4

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis

NCT04118010

COMPLETED NA

Out of Pocket Cost Communication in Multiple Sclerosis Patients

NCT04257071

COMPLETED Phase 4

Biomarkers for Event-driven PrEP Adherence

NCT04298697

COMPLETED NA

Mental Stress and Myocardial Ischemia After MI: Sex Differences, Mechanisms and Prognosis

NCT04123197

COMPLETED NA

Life Care Specialists (LCS) With a Focus on Patient Pain Management and Prevention of Substance Misuse

NCT04154384

COMPLETED NA

Implementation of Rapid HIV Self-Testing Among MSM Project

NCT04219878

COMPLETED NA

SPIRIT for Persons With Dementia and Complex Multimorbidity

NCT04108000

COMPLETED NA

Dry Needling for Cervicogenic Headache

NCT04305223

COMPLETED NA

Comparison of Dietary Sugar Reduction Methods

NCT04186793

TERMINATED

Solid Organ Transplant SHINGRIX

NCT03993717

COMPLETED NA

HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)

NCT03763942

TERMINATED Phase 2

AflacLL1901 (CHOA-AML)

NCT04326439

COMPLETED NA

Hemodynamics Measurement in Radiofrequency Catheter Ablation

NCT04227119

COMPLETED Phase 1

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

NCT04191421

COMPLETED NA

Effects of Sensory Flicker and Electrical Flicker Stimulation

NCT04188834

COMPLETED NA

Mindfulness IN-home for Diabetes and Sleep Health

NCT04160078

COMPLETED NA

Vertebral Body Sparing Craniospinal Irradiation for Pediatric Patients With Cancer of the Central Nervous System

NCT04276194

COMPLETED NA

Low-dose Y90 Treatment Planning for HCC

NCT04172714

COMPLETED NA

Cortical Contributions to Motor Sequence Learning

NCT04138953

COMPLETED Phase 4

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

NCT04157738

COMPLETED Phase 2

Systems Biology of Zoster Vaccine

NCT04047979

COMPLETED Phase 2

Symptom Clusters in Children With Exacerbation-prone Asthma

NCT04002362

COMPLETED Early Phase 1

Neuroendocrine Risk for PTSD in Women

NCT03973229

TERMINATED NA

Safety and Effectiveness of the Peregrine Drivable ENT Scope for Endoscopy of the Paranasal Sinuses

NCT04096482

COMPLETED

Quantification of Myocardial Blood Flow Using Dynamic PET/CTA Fused Imagery

NCT04221594

COMPLETED NA

Soccer Intervention in Prostate Cancer Survivors

NCT04144127

COMPLETED Phase 4

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

NCT04080531

COMPLETED NA

Dialectical Behavior Therapy for Pregnant Women

NCT03938350

TERMINATED NA

The Use of 3D Printing in Orbital Fractures

NCT03673865

COMPLETED Phase 4

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

NCT04039217

COMPLETED Phase 2

Montelukast Therapy on Alzheimer's Disease

NCT03991988

← Previous Page 9 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Emory University pipeline card: 1,208 registered trials from official public datasets.Report a data error.